Dysadherin and Colorectal Cancer Prognosis
Author Information
Author(s): S Aoki, T Shimamura, T Shibata, Y Nakanishi, Y Moriya, Y Sato, M Kitajima, M Sakamoto, S Hirohashi
Primary Institution: National Cancer Center Research Institute, Tokyo, Japan
Hypothesis
Dysadherin expression may play a significant role in the aggressiveness of colorectal carcinoma.
Conclusion
Increased dysadherin expression is significantly correlated with poor survival in patients with advanced colorectal carcinoma.
Supporting Evidence
- Patients with dysadherin immunopositivity in over 50% of tumour cells survived significantly shorter than those with fewer than 50%.
- Reduced E-cadherin immunopositivity was correlated with poor survival.
- Patients with both increased dysadherin and reduced E-cadherin expression had the worst prognosis.
Takeaway
Dysadherin is a protein that can help doctors understand how aggressive a colorectal cancer is, and higher levels of it mean a worse outcome for patients.
Methodology
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded colorectal carcinoma tissues to evaluate dysadherin and E-cadherin expression.
Limitations
The study was limited to patients who underwent curative resection and did not receive preoperative chemotherapy or radiation therapy.
Participant Demographics
44 men and 38 women, ages 37 to 93 years, mean age 62.6 years.
Statistical Information
P-Value
P=0.0099
Confidence Interval
95% CI: 1.032–11.851
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website